Sensitrin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sensitrin

Property Description
Active Ingredient Levocetirizine dihydrochloride
Form Film-coated tablets, Oral solution
Pharmacological Class Second-generation Antihistamine
Common Use Relief of general allergy symptoms
Origin Synthetic, R-enantiomer (chiral switch)

Sensitrin: Definition and Pharmacological Class

Sensitrin is a medicinal preparation whose active component, levocetirizine dihydrochloride, classifies it as a second-generation antihistamine. Structurally, it is a highly selective histamine H1 receptor antagonist designed for systemic use against allergic manifestations. The drug is synthetic and represents the purified, active R-enantiomer of cetirizine, which is often termed a "chiral switch" product. Its definitive classification places it as a modern, targeted agent used to manage conditions stemming from the body's overreaction to allergens.


Composition and Available Forms

The core composition of Sensitrin is a single active ingredient, levocetirizine dihydrochloride, which is presented in multiple forms for oral delivery. As a monotherapy, it contains no other active compounds, focusing entirely on the anti-allergic action of the levocetirizine substance. Sensitrin is commonly available as film-coated tablets and as an oral solution (a liquid form). The oral solution form allows for precise dosing in pediatric patients. This range of dosage forms is offered to ensure flexible and accurate oral route of administration for different patient demographics, including adults and pediatric patients, facilitating consistent systemic absorption of the drug.


General Purpose and Anti-Allergic Action

The general purpose of Sensitrin is to provide relief from the core symptoms associated with various allergic reactions. Levocetirizine is used to provide relief against the discomfort of seasonal allergies. The benefit is achieved through its fundamental function: levocetirizine intervenes chemically by blocking the action of histamine, which is the primary chemical messenger that the body releases upon allergen exposure. By inhibiting the access of histamine to its specific receptors, Sensitrin helps stabilize the allergic response, which generally leads to the reduction of typical discomforts, such as itching, sneezing, and watery eyes. This targeted action helps reduce allergy-related irritation, making it a common choice for scenarios involving chronic skin itching or persistent runny nose.

Regulatory References

  1. FDA label for Levocetirizine oral solution

What side effects are possible with Sensitrin?

Possible Side Effects and Safety Information

The safety profile of Sensitrin (levocetirizine dihydrochloride) is established through clinical studies and post-marketing surveillance, as documented by official regulatory bodies. Adverse reactions are classified according to frequency and the affected system-organ class.


Frequency-Classified Adverse Reactions

Adverse effects identified in clinical trials are categorized into standard frequency tiers:

Frequency Classification Adverse Reactions (Example Terminology)
Common (ge 1/100 to < 1/10) Somnolence, Fatigue, Dry mouth, Headache, Pharyngitis
Uncommon (ge 1/1,000 to < 1/100) Asthenia, Abdominal pain

Events reported post-marketing, such as Aggression, Insomnia, Hepatitis, Convulsion, and Urinary retention, are also documented, although their frequency is classified as Not Known (cannot be estimated from available data).


Serious Reactions and Safety Constraints

Serious adverse reactions officially listed include Hypersensitivity reactions such as anaphylaxis and angioneurotic oedema (severe localized swelling). These are reported in the post-marketing setting.

Specific regulatory safety constraints exist for certain patient populations and conditions:

  • Renal Impairment: Sensitrin is contraindicated in patients with End-Stage Renal Disease (very severe kidney impairment) and requires dose adjustment in all other adult patients with reduced renal function.
  • Predisposing Factors: Caution is advised in patients with risk factors for urinary retention or a history of epilepsy, as the medication may increase risk in these areas.
  • Discontinuation Pattern: A potential for new onset pruritus (itching) has been reported in individuals upon stopping treatment following long-term use.

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected overdose of Sensitrin (levocetirizine) requires immediate medical attention. Contact emergency services or a poison control center for guidance. This is the mandatory course of action established by regulatory authorities due to the potential for severe outcomes.

Documented Clinical Signs:

Overdose manifestations primarily affect the Central Nervous System (CNS) and vary by age. In adults, the most commonly documented sign is somnolence (drowsiness). In pediatric patients, overdose may present initially with agitation and restlessness, which is then followed by somnolence. Other potential signs listed in regulatory documents include tachycardia (increased heart rate) and tremor.

Official Management and Limitations:

The mandated management approach is symptomatic and supportive treatment. Regulatory labels explicitly state that no specific antidote is known for levocetirizine overdose. Additionally, the drug is not effectively removed by dialysis. In certain situations, interventions such as gastric lavage or administration of activated charcoal may be considered to limit systemic absorption. Hospital monitoring may be required for observation following an acute overdose. Patients with impaired renal function are recognized as a population at increased risk for drug accumulation in an overdose scenario.

Therapeutic Uses of Sensitrin

What Sensitrin Treats: Main Uses and Benefits

Sensitrin is commonly used to help with symptomatic relief across the primary therapeutic domains involving chronic and episodic allergic conditions, assisting patients with managing symptoms that interfere with daily functioning. The medication (levocetirizine) is commonly used to help with symptomatic relief across key domains, including allergic rhinitis and chronic idiopathic urticaria (CIU). The intent of use is to ease the impact of bothersome symptoms on routine activities and general comfort. The medication helps address core symptom clusters, including frequent sneezing, bothersome runny nose, intense pruritus affecting the nose and eyes, and the appearance of hives.

Sustained Symptom Control

This supportive benefit helps maintain a sense of stability when symptoms become more noticeable. The medication is considered relevant for conditions characterized by periods of heightened symptoms that require consistent symptomatic support. Offering consistency in symptomatic relief supports patients during difficult episodes and contributes to improved day-to-day comfort.


Quick Fact: Relief for Persistent Itching

Sensitrin is commonly used to ease the intense, widespread pruritus (skin itching) associated with chronic hives, helping to reduce this significant symptom burden.

Regulatory References

  1. NIH MedlinePlus overview of Levocetirizine Use

Eligibility and Restrictions for Use

Eligibility for Sensitrin Use

Sensitrin, which contains levocetirizine dihydrochloride, is approved for use in adults and children 6 years of age and older for certain conditions (such as chronic idiopathic urticaria and allergic rhinitis). For the oral solution form, the approved eligibility extends to children as young as 6 months of age for specific indications. The appropriate dosage for pediatric patients, especially those under 6 years, often requires a specific liquid formulation as the tablets do not allow for the necessary dose adjustment.

Contraindicated and Restricted Populations

Official regulatory labeling dictates that Sensitrin is contraindicated and must not be used by specific groups due to safety and elimination risks:

  • Hypersensitivity: Patients who have a known allergy to levocetirizine, any of the medication's ingredients, or to the related antihistamine, cetirizine.
  • Severe Renal Impairment: Patients with end-stage renal disease (creatinine clearance less than 10 mL/min) and those undergoing hemodialysis.
  • Pediatric Renal Impairment: Children aged 6 months to 11 years who have any degree of impaired kidney function.

Use is not recommended or requires special consideration for individuals with predisposing factors for urinary retention, such as spinal cord lesions or an enlarged prostate, as the medication may increase this risk. While clinical data does not indicate a risk of birth defects during pregnancy, levocetirizine is not recommended for use while breastfeeding as it can pass into breast milk.

What should I know about interactions with other medicines?

Sensitrin Interactions with other medicines and products

Sensitrin’s (levocetirizine) official interaction profile is characterized by its low metabolic liability and primary reliance on renal excretion. Regulatory documents classify interactions across pharmacodynamic effects and altered drug clearance.

Interaction Type Interacting Products/Substances Regulatory Requirement
Pharmacodynamic Risk Alcohol, CNS Depressants (e.g., tranquilizers) Avoid Co-administration
Pharmacokinetic Alteration Ritonavir, Theophylline Use with Caution/Monitoring
Timing/Absorption High-fat Food Intake No separation required

Regulatory-Specific Constraints

Pharmacodynamic Interactions (Avoidance Required): Co-administration with alcohol or other Central Nervous System (CNS) depressants is officially restricted. This prohibition is due to the documented risk of additive impairment of central nervous system performance and additional reductions in alertness.

Exposure-Modifying Interactions: Studies with the parent compound, cetirizine, documented that co-administration with Ritonavir or Theophylline increases the plasma AUC (exposure) by reducing clearance. This requires monitoring due to potential accumulation.

Excretion and Condition-Based Restrictions: The use of Sensitrin is formally contraindicated in individuals with End-Stage Renal Disease (creatinine clearance < 10 mL/min) due to the substantial risk of accumulation. Patients with any degree of renal impairment (CLCR < 80 mL/min) are subject to official requirements for interval adjustment, as clearance is reduced in this population. Although a high-fat meal delays the time to maximum concentration (Tmax) and lowers the Cmax, the overall extent of absorption (AUC) is unaffected, meaning no mandatory dose separation is needed.

Mechanism of Action

A1R Receptor Antagonism

Sensitrin acts via a specific mechanism that modulates signaling pathways involved in bone remodeling. It achieves this by functioning as an antagonist of the A1R receptor, which is expressed on specific bone cells.


NFkappa B Pathway Modulation

The A1R receptor antagonism results in decreased NFkappa B signaling within osteoclast precursor cells. This molecular action limits the proliferation and differentiation of these cells, which are responsible for bone resorption.


Influence on Bone Dynamics

This cascade of events decreases the overall ratio of bone resorption to bone formation. The resulting action on cell activity thus influences cellular processes that regulate mineral homeostasis and bone tissue turnover.

Dosage and Administration Information

Sensitrin, containing levocetirizine dihydrochloride, is administered exclusively via the oral route for systemic use. The standard daily regimen for adults and adolescents (12 years and older) is 5 mg. A 2.5 mg dose may be appropriate for individuals with less severe symptoms, but the maximum daily dose remains 5 mg. The medication should be taken once daily, often advised for administration in the evening, and intake is not dependent on meals, as the drug can be consumed without regard to food.

The official preparation offers two forms to ensure accurate dosing. The 5 mg film-coated tablet is scored to facilitate division into 2.5 mg halves. An oral solution (0.5 mg/ mL) is also available, primarily used for precise liquid measurement in pediatric patients.

Dosing guidelines involve adjustments for specific age groups. For children aged 6 to 11 years, the official daily dose is 2.5 mg. For the youngest patients, from 6 months to 5 years, the dose is 1.25 mg once daily, requiring the use of the oral solution for accuracy.

A critical procedural constraint involves renal function. The required dose and frequency are strictly contingent upon the patient's measured Creatinine Clearance (Clcr). Patients with reduced kidney function require a lower dose or an extended dosing interval. Use is officially restricted for individuals with severe renal impairment (Clcr less than 10 mL/ min) or those undergoing hemodialysis. Conversely, no dose alteration is necessary for isolated hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Sensitrin

Evidence for Symptom Control in Allergic Rhinitis

This section summarizes the structure of the clinical research, focusing on the large, randomized controlled trials and systematic reviews that have evaluated Sensitrin for symptoms of seasonal and perennial allergic rhinitis. It describes the key outcomes measured in these studies, such as total symptom scores and quality of life assessments.

The evidence base for allergic rhinitis largely relies on Randomized Controlled Trials (RCTs). Researchers examined patient-reported outcomes describing perceived discomfort related to physical discomfort like sneezing, runny nose, and ocular itching. Trials included many participants, encompassing adults, adolescents, and children, to study conditions characterized by fluctuating or episodic manifestations.

Trials reported measurements of symptom change, including patterns related to lower patient-reported severity of nasal and ocular itching. Sensitrin was observed in studies focusing on episodes where symptoms become heightened. However, the evidence is limited regarding the long-term effects of use, as follow-up durations were limited in many initial trials.


Evidence for Managing Chronic Hives (Chronic Idiopathic Urticaria)

This section outlines the evidence base, including the placebo-controlled trials and comparative studies, that specifically evaluated Sensitrin for Chronic Idiopathic Urticaria (CIU). It details the specific metrics used by researchers to measure changes in skin-related symptoms, such as the severity of itching (pruritus) and the appearance of wheals.

Research examined Sensitrin for conditions involving periods of heightened symptoms such as chronic hives. Studies explored outcomes related to physical discomfort, specifically patient-reported outcomes describing perceived discomfort from itching and the size and frequency of wheals (hives). Studies report how symptoms evolved in the observed populations over defined time intervals, typically less than three months.

The evidence quality varies across studies, and sample sizes were modest in some trials. Follow-up durations were limited, meaning that long-term effects are not fully established regarding symptom patterns after the observation period ends. Furthermore, data for certain groups remain insufficient, specifically for patients whose chronic hives were observed to be refractory (unresponsive) to standard starting doses.


Summary of Research Gaps and Uncertainties

This final section provides a neutral summary of the main limitations and knowledge gaps identified in the regulatory and peer-reviewed literature. Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain.

The primary limitation consistently cited in the evidence landscape is that long-term effects are not fully established, as follow-up durations were limited in many primary studies. Comparative evidence is lacking for a comprehensive, head-to-head comparison against all alternative second-generation antihistamines currently on the market. Data for certain special populations, such as pregnant individuals, remain insufficient or were not the primary focus of the clinical research base.

Key Studies & References

  1. Levocetirizine for seasonal allergic rhinitis: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Sensitrin (FAQ)


Q: Is Sensitrin a short-term or long-term treatment?

Sensitrin is indicated for the relief of symptoms related to conditions like allergic rhinitis and chronic idiopathic urticaria (hives), which may require short-term or ongoing management. According to official research documents, the long-term effects beyond the initial study periods are not fully established. Therefore, regulatory information focuses on use for defined symptom control.


Q: Does Sensitrin need to be taken with food?

No, official product information states that Sensitrin can be taken without regard to food. Although a high-fat meal may slightly delay the time the medicine reaches its highest concentration in the body, the overall amount of the drug absorbed remains unchanged.


Q: Is there a generic version of Sensitrin available?

Yes, the active ingredient in Sensitrin is levocetirizine dihydrochloride. This active ingredient is available in generic versions, in addition to the original brand name product.


Q: Can Sensitrin be used by children?

Official labeling indicates that Sensitrin is approved for use in adults and children 6 years of age and older for conditions like allergic rhinitis and chronic hives. The liquid oral solution form is also approved for specific indications in children as young as 6 months of age.


Q: Can Sensitrin be taken by pregnant or breastfeeding individuals?

Regarding pregnancy, available human data does not currently suggest an increased risk of birth defects. For breastfeeding, the drug can pass into breast milk, and its use is generally not recommended. Regulatory labeling indicates that such decisions require input from a healthcare professional.


Q: Can alcohol be consumed while on Sensitrin?

Regulatory documents state that the consumption of alcohol while using Sensitrin should be avoided. This is because alcohol can increase the risk of reduced central nervous system performance and lead to additional impairment of alertness.


Q: Does Sensitrin interact with common over-the-counter pain relievers like ibuprofen?

Official drug interaction studies do not typically report a specific interaction between Sensitrin’s active ingredient and common non-prescription pain relievers like ibuprofen or acetaminophen. However, regulatory warnings exist for possible additive effects when combined with central nervous system (CNS) depressants.


Q: Can I stop taking Sensitrin suddenly if I feel better?

Regulatory warnings mention that some people, particularly after long-term use of Sensitrin, have reported developing new or worsening itching (pruritus) shortly after stopping treatment. This information is noted in safety documents related to discontinuation patterns.


Q: Do any official documents describe the potential for dependence on Sensitrin?

Sensitrin (levocetirizine) is not classified as a controlled substance by regulatory bodies like the U.S. Drug Enforcement Administration. Official information does not associate this medication with the potential for physical dependence.


Q: What should I look for if I suspect an interaction with another drug?

Interactions often present as an increase in typical side effects. The regulatory warnings primarily highlight signs of increased central nervous system depression, such as excessive sleepiness or significant reductions in alertness.


Q: Why is a specific patient population excluded from using Sensitrin?

Sensitrin is contraindicated, or forbidden, for patients who have severe renal impairment (end-stage kidney disease). This is because the drug is removed from the body primarily by the kidneys, and severe impairment carries a substantial risk of drug accumulation and adverse reactions.


Q: Is it possible to take too much Sensitrin?

Yes, it is possible to take an excessive amount (an overdose) of Sensitrin. In adults, the main symptom reported is extreme sleepiness, while in young children, symptoms may include restlessness or agitation before drowsiness sets in.


Q: How quickly can I expect Sensitrin to start working?

Official pharmacokinetic studies indicate that Sensitrin is rapidly absorbed after administration. Peak concentrations of the medication in the bloodstream are typically reached in less than one hour after taking the oral tablet.


Q: Will Sensitrin change how my body processes other medications?

The official product information notes that Sensitrin is mainly excreted unchanged by the kidneys, with only a small fraction (less than 14%) being metabolized. This low metabolic extent suggests a low likelihood of significantly altering the way the body processes other medications through the primary liver enzyme systems.


Q: Is it common to feel tired or dizzy when taking Sensitrin?

Official safety data lists somnolence (sleepiness) and fatigue as common adverse reactions. Post-marketing surveillance reports have also included hypotension (low blood pressure) as a serious reaction which can sometimes lead to feelings of lightheadedness or dizziness, though its frequency is unknown.


Q: Can Sensitrin affect my ability to drive or operate machinery?

Official warnings exist regarding participation in activities that demand complete mental alertness and motor coordination, such as driving or operating heavy machinery. This is due to the reported risk of sleepiness, fatigue, and potential reduction in central nervous system performance.


Q: How long after stopping Sensitrin does it stay in my system?

The average elimination half-life of Sensitrin in adults with normal kidney function is approximately 8 to 10 hours. It generally takes about four to five half-lives for the majority of any medication to be cleared from the body.


Q: Do regulators require any special monitoring while taking Sensitrin?

Official labeling requires that dose adjustments be made based on a patient's measured kidney function, necessitating the monitoring of this function in adults with renal impairment. However, general, routine blood testing is not universally required for all patients.


Q: Are there known differences in how Sensitrin works in different patient groups?

Official pharmacokinetic studies indicate that clearance rates and peak concentrations can differ among age groups. For instance, children aged 6 to 11 years may have a faster clearance than adults, and older adults may have a reduced clearance due to typical age-related changes in kidney function.


Q: Does taking Sensitrin affect blood pressure or heart rate?

Official post-marketing surveillance reports include hypotension (low blood pressure) as a serious adverse reaction, meaning it has been reported, but its frequency is classified as not known and cannot be estimated from the available data.


Q: Can Sensitrin interact with certain types of laboratory tests?

Sensitrin is an antihistamine and can interfere with the results of allergy skin tests, potentially causing false negative results. Regulatory labeling addresses the need to discontinue the drug for a specific period before such testing to ensure accuracy.


Q: Does Sensitrin have any known effects on weight gain or loss?

Weight gain is not listed among the common or uncommon side effects identified in clinical trials. However, post-marketing surveillance sometimes includes weight-related effects, though their frequency is classified as 'Not Known' (meaning it cannot be estimated from available data).


Q: Are there specific foods or beverages that interact with Sensitrin?

Official product information states that Sensitrin can be taken without regard to food, as food does not significantly impact the overall absorption of the drug. Alcohol is the only substance specifically restricted due to its potential to cause additive central nervous system effects.


Q: Is Sensitrin a controlled substance?

No, Sensitrin is not classified as a controlled substance by regulatory bodies such as the U.S. Drug Enforcement Administration. Official labeling does not associate the medication with abuse potential or dependence.


Q: How does Sensitrin affect mood or mental alertness?

The drug can cause somnolence (sleepiness) and fatigue, which affect mental alertness. Official post-marketing reports have also included mood changes such as aggression, depression, and hallucinations, though the frequency of these specific effects is classified as 'Not Known.'


Q: Why do some people need a higher dose than others according to the research?

Official labeling for adults and adolescents states that the standard dose is 5 mg, but notes that some individuals may respond to a lower dose of 2.5 mg. This indicates that individual variability in response is a known factor in determining the appropriate dosage.

How should Sensitrin be stored and disposed of?

How to Store and Dispose of Sensitrin

Official regulatory documents define strict conditions for the storage and disposal of Sensitrin (levocetirizine).

Storage Requirements

The medicine must be stored at Controlled Room Temperature, which is maintained between 20 C and 25 C (68 F to 77 F). Storage excursions are permitted between 15 C and 30 C.

The product must be kept in its original container and protected from moisture and excess heat; it must not be frozen.

Stability and Child Safety

For the oral solution, the product must be discarded 14 days after the first opening. All forms of Sensitrin must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired product must not be disposed of in wastewater (flushed down a toilet or poured down a sink). Disposal should be carried out through a pharmacy-led drug take-back program or specialized collection system according to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sensitrin found in:

A-Z Index: